Health Catalyst’s (HCAT) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Health Catalyst (NASDAQ:HCAT) in a research report report published on Tuesday,Benzinga reports. Piper Sandler currently has a $12.00 target price on the stock, up from their previous target price of $11.00.

A number of other research analysts have also issued reports on HCAT. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI raised their target price on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Stephens lifted their target price on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Citigroup increased their price target on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Stock Up 1.8 %

Shares of Health Catalyst stock opened at $8.65 on Tuesday. The stock has a market capitalization of $526.34 million, a price-to-earnings ratio of -6.41 and a beta of 1.32. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The business’s 50 day simple moving average is $8.12 and its 200-day simple moving average is $7.31.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.22) earnings per share. Equities research analysts forecast that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Activity

In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the transaction, the chief operating officer now owns 134,899 shares in the company, valued at approximately $1,036,024.32. This trade represents a 3.72 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,068 shares of company stock worth $257,555. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently modified their holdings of HCAT. Quest Partners LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC boosted its holdings in shares of Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the period. Quarry LP increased its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Health Catalyst during the third quarter valued at approximately $59,000. Finally, Perfromance Wealth Partners LLC purchased a new stake in shares of Health Catalyst in the 2nd quarter valued at approximately $64,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.